Who is sponsoring NCT06778538?

NCT06778538 is sponsored by Shang Panfeng.

What drugs are being tested in NCT06778538?

Interventions in NCT06778538: Immunohistochemistry; WB; PCR.

What condition does NCT06778538 study?

NCT06778538 studies Clear Cell Renal Cell Carcinoma (ccRCC).

Is NCT06778538 still recruiting?

NCT06778538 is currently completed. Last updated 16 January 2025.

Last reviewed 2025-01-16 · How we verify

NCT06778538: HPGD-ccRCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients

Completed Last updated 16 January 2025

What this trial tests

trial testing Immunohistochemistry; WB; PCR in Clear Cell Renal Cell Carcinoma (ccRCC) in 40 participants. Completed in 20 November 2024.

Timeline

1 July 2024

Primary endpoint
1 November 2024

20 November 2024

Quick facts

Lead sponsor	Shang Panfeng
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 July 2024
Primary completion	1 November 2024
Estimated completion	20 November 2024
Sites	1 location across China

Drugs / interventions tested

Immunohistochemistry; WB; PCR

Conditions studied

Clear Cell Renal Cell Carcinoma (ccRCC) — all drugs for Clear Cell Renal Cell Carcinoma (ccRCC) →

Sponsor

Shang Panfeng

Who can join

18 and older, any sex, with Clear Cell Renal Cell Carcinoma (ccRCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the role of HPGD in clear cell renal cell carcinoma (ccRCC). Specifically, it will focus on HPGD's impact on proliferation, epithelial-mesenchymal transition (EMT), and prognosis. The study will analyze gene expression data from clinical samples and use techniques like RT-qPCR, Western blotting, and immunohistochemistry to assess HPGD expression levels. Additionally, the research will explore the relationship between HPGD and patient survival outcomes. By elucidating HPGD's contribution to cancer progression, the study seeks to identify potential therapeutic targets for improving renal cancer treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Clear Cell Renal Cell Carcinoma (ccRCC)

Currently open trials in the same condition.

NCT07386158 — Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
NCT05176483 — Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors · Phase 1 · recruiting
NCT03972657 — A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for A · Phase 1, PHASE2 · recruiting
NCT03634540 — A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinom · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06778538 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shang Panfeng
Last refreshed: 16 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06778538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing